Dr Tyler Wish is a Canadian biotechnology entrepreneur focused on data-driven medicine and computational drug discovery who received his PhD in medicine from Memorial University. He is the CEO of NACBio, a privately-held cannabis intelligence firm that is engineering a deeper data-driven understanding of the relationship between cannabis and human biology.
Tyler previously co-founded Sequence Bio, a biotechnology company that led Newfoundland’s 100,000 person genome sequencing initiative designed to advance big data drug discovery. Over the years, he and the company were profiled at numerous industry, investment and public-policy forums including BIO Investor Forum, The Precision Medicine World Conference, Canada 2020, and Bloomberg TV.
A key player in the broader Canadian innovation ecosystem, Tyler supported recent Federal Legislation (Genetic Non-Discrimination Act), was a member of BIOTECanada’s Emerging Company CEO Advisory Committee, and was appointed as one of ten Canadian Innovation Leaders by the Federal Minister of Innovation, Science and Economic Development. He is currently a board member for the Board of Actua, Canada’s leading youth STEM education outreach organization.